LRRK2

Related Products

Leucine-rich repeat kinase 2 (LRRK2) is an enzyme that in humans is encoded by the PARK8 gene. LRRK2 is a member of the leucine-rich repeat kinase family. Variants of this gene are associated with an increased risk of Parkinson's disease (PD)and also Crohn's disease (CD).

Leucine-rich repeat kinase 2 (LRRK2) is the gene responsible for autosomal-dominant PD, PARK8, which is originally defined by linkage analysis of a Japanese family. LRRK2 is a complex kinase consisting of LRR, ROC, COR, kinase, and WD40 domains. LRRK2 plays a key role in axonal extension, autophagy, proliferation, and survival of neurons. In addition to neurons, LRRK2 is highly expressed in immune cells such as B cells, macrophages, and microglia. Several studies have demonstrated that LRRK2 is related to inflammatory responses of microglia that could be involved in the development and progression of neurodegeneration.

LRRK2 is a large, multidomain protein containing two catalytic domains: a Ras of complex proteins (Roc) G-domain and a kinase domain. Leucine-rich repeat kinase 2 (LRRK2) represents a promising drug target for treatment and prevention of Parkinson’s disease (PD), because mutations in LRRK2 are the most common cause of Mendelian forms of the disease. PD-associated LRRK2 variants show decreased GTPase and increased kinase activity.

LRRK2 Related Products (17):

Cat. No.	Product Name	Effect	Purity

HY-100411

MLi-2 Inhibitor 99.66%

MLi-2 is a potent, highly selective, orally available, brain penetrant inhibitor of LRRK2 with an IC₅₀ of 0.76 nM.

MLi-2	Inhibitor	99.66%
MLi-2 is a potent, highly selective, orally available, brain penetrant inhibitor of LRRK2 with an IC₅₀ of 0.76 nM.

HY-13687

IKK 16	Inhibitor	99.09%
IKK 16 is a selective IκB kinase (IKK) inhibitor for IKK2, IKK complex and IKK1 with IC₅₀s of 40 nM, 70 nM and 200 nM, respectively. IKK16 also inhibits leucine-rich repeat kinase-2 (LRRK2) with an IC₅₀ of 50 nM.

HY-12477

PF-06447475 Inhibitor 99.88%

PF-06447475 is a highly potent, selective and brain penetrant LRRK2 inhibitor with an IC₅₀ of 3 nM.
HY-10875

LRRK2-IN-1 Inhibitor 99.19%

LRRK2-IN-1 is a potent and selective LRRK2 inhibitor with IC₅₀ of 6 nM and 13 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.
HY-13237

GSK2578215A Inhibitor 99.86%

GSK2578215A is a potent and highly selective LRRK2 inhibitor, which exhibits IC₅₀s of around 10 nM against both wild-type LRRK2 and the G2019S mutant.
HY-15796

GNE0877 Inhibitor 98.64%

GNE0877 is a highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitor with an IC50 of 3 nM.
HY-18163

GNE-7915 Inhibitor 99.48%

GNE-7915 is a potent, selective and brain-penetrant inhibitor of LRRK2 with an IC₅₀ of 9 nM.

PF-06447475	Inhibitor	99.88%
PF-06447475 is a highly potent, selective and brain penetrant LRRK2 inhibitor with an IC₅₀ of 3 nM.

LRRK2-IN-1	Inhibitor	99.19%
LRRK2-IN-1 is a potent and selective LRRK2 inhibitor with IC₅₀ of 6 nM and 13 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.

GSK2578215A	Inhibitor	99.86%
GSK2578215A is a potent and highly selective LRRK2 inhibitor, which exhibits IC₅₀s of around 10 nM against both wild-type LRRK2 and the G2019S mutant.

GNE0877	Inhibitor	98.64%
GNE0877 is a highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitor with an IC50 of 3 nM.

GNE-7915	Inhibitor	99.48%
GNE-7915 is a potent, selective and brain-penetrant inhibitor of LRRK2 with an IC₅₀ of 9 nM.

HY-120085

PFE-360	Inhibitor	98.94%
PFE-360 (PF-06685360) is a potent, selective, brain penetrated and orally active leucine-rich repeat kinase 2 (LRRK2) inhibitor with a mean IC₅₀ of 2.3 nM in vivo.

HY-16936

JH-II-127	Inhibitor	98.66%
JH-II-127 is a highly potent, selective, and brain penetrant LRRK2 inhibitor, with IC50 of 6.6 nM, 2.2 nM ,47.7 nM for LRRK2-wild-type, LRRK2-G2019S, LRRK2-A2016T.

HY-12282

GNE-9605 Inhibitor 99.37%

GNE-9605 is a highly potent, selective, and brain-penetrant LRRK2 inhibitor with IC50 of 19 nM.
HY-B0792

CZC-54252 Inhibitor 99.26%

CZC-54252 is a potent inhibitor of LRRK2 with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2 respectively.

GNE-9605	Inhibitor	99.37%
GNE-9605 is a highly potent, selective, and brain-penetrant LRRK2 inhibitor with IC50 of 19 nM.

CZC-54252	Inhibitor	99.26%
CZC-54252 is a potent inhibitor of LRRK2 with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2 respectively.

HY-13488

HG-10-102-01	Inhibitor	99.57%
HG-10-102-01 is a potent and selective inhibitor of wild-type LRRK2(IC50=23.3 nM) and the G2019S mutant(IC50=3.2 nM) IC50 Value: 23.3 nM (WT LRRK2); 3.2 nM (LRRK2 G2019S) [1] Target: LRRK2 HG-10-102-01 maintains the ability to potently inhibit the biochemical activity of wild-type and G2019S mutant LRRK2.

HY-15800A

CZC-25146 Inhibitor 98.64%

CZC-25146 is a potent, selective and metabolically stable LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively.
HY-111493

LRRK2 inhibitor 1 Inhibitor 99.72%

LRRK2 inhibitor 1 is a potent, selective and oral LRRK2 inhibitor with an pIC₅₀ of 6.8 nM.
HY-18163A

GNE-7915 tosylate Inhibitor 99.62%

GNE-7915 tosylate is a potent, selective and brain-penetrant inhibitor of LRRK2 with an IC₅₀ of 9 nM.

CZC-25146	Inhibitor	98.64%
CZC-25146 is a potent, selective and metabolically stable LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively.

LRRK2 inhibitor 1	Inhibitor	99.72%
LRRK2 inhibitor 1 is a potent, selective and oral LRRK2 inhibitor with an pIC₅₀ of 6.8 nM.

GNE-7915 tosylate	Inhibitor	99.62%
GNE-7915 tosylate is a potent, selective and brain-penetrant inhibitor of LRRK2 with an IC₅₀ of 9 nM.

HY-13687A

IKK 16 hydrochloride	Inhibitor
IKK 16 hydrochloride is a selective IκB kinase (IKK) inhibitor for IKK2, IKK complex and IKK1 with IC₅₀s of 40 nM, 70 nM and 200 nM, respectively. IKK16 also inhibits leucine-rich repeat kinase-2 (LRRK2) with an IC₅₀ of 50 nM.

HY-15800

CZC-25146 hydrochloride	Inhibitor
CZC-25146 Hcl is a potent, selective and metabolically stable LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively.

Name
Email *

	Sorry, but the email address you supplied was invalid.